Entecavir-13C2,15N

Entecavir-13C2,15N (BMS200475-13C2,15N; SQ34676-13C2,15N) is a 13C- and 15N-labeled Entecavir (HY-13623) . Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.

Product Specifications

Product Name Alternative

BMS200475-13C2,15N; SQ34676-13C2,15N

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HBV; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/entecavir-13c2-15n.html

Solubility

10 mM in DMSO

Smiles

O[C@H]([C@H]1CO)C[C@H](N2[13C]3=C([13C](NC(N)=N3)=O)[15N]=C2)C1=C

Molecular Formula

C10 13C2H15N4 15NO3

Molecular Weight

280.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-246.|[2]Innaimo SF, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41 (7) :1444-9.|[3]Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin. 2005 Nov;21 (11) :1845-57.|[4]Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother. 1998 Dec;42 (12) :3209-18.